MCID: PLS009
MIFTS: 51

Plasma Cell Neoplasm

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 15 17 71
Plasma Cell Dyscrasia 12 71
Paraproteinemias 43 71
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 71
Plasmacytoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 43 D010265
NCIt 49 C4665
UMLS 71 C0026764 C0030489 C0032131 more

Summaries for Plasma Cell Neoplasm

Disease Ontology : 12 A mature B-cell neoplasm that is composed of plasma cells.

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to monoclonal paraproteinemia and plasma cell leukemia. An important gene associated with Plasma Cell Neoplasm is IL6 (Interleukin 6), and among its related pathways/superpathways are Allograft rejection and Measles. The drugs Phentolamine and Apixaban have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotype is neoplasm.

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 619)
# Related Disease Score Top Affiliating Genes
1 monoclonal paraproteinemia 34.4 SDC1 NCAM1 IGHV4-38-2 CD79A CD40LG
2 plasma cell leukemia 33.2 SDC1 NCAM1 MYC MIR125A IL6 CD38
3 waldenstroem's macroglobulinemia 33.1 SDC1 MYOM2 IGHV4-38-2 CD79A CD40LG CD38
4 plasmacytoma 32.9 PVT1 PTPRC NCAM1 MYC IL6 CD79A
5 myeloma, multiple 31.8 SDC1 PVT1 PTPRC NCAM1 MYOM2 MYC
6 extramedullary plasmacytoma 31.7 SDC1 NCAM1 MYOM2 MAEA IL6 CD79A
7 osteosclerotic myeloma 31.3 MYOM2 MAEA CD40LG
8 pyoderma 31.3 MYOM2 CXCL8 CD40LG
9 purpura 31.1 IL6 CD79A CD40LG
10 macroglobulinemia 31.0 SDC1 IL6 CD40LG
11 cryoglobulinemia 30.9 IL6 CD79A CD40LG
12 exanthem 30.9 IL6 ICOSLG CXCL8 CD40LG
13 smoldering myeloma 30.9 SDC1 NCAM1 MYOM2 IGHV4-38-2 CD40LG CD38
14 fasciitis 30.9 MYOM2 IL6 CXCL8
15 polyclonal hypergammaglobulinemia 30.8 MYOM2 IL6 CD40LG
16 cryofibrinogenemia 30.8 CD79A CD40LG
17 indolent myeloma 30.8 MYOM2 IL6
18 myositis 30.8 NCAM1 IL6 ICOSLG CXCL8
19 amyloidosis 30.7 MYOM2 IL6 CD40LG B2M
20 dermatitis herpetiformis 30.7 CXCL8 CD79A CD40LG
21 plasmablastic lymphoma 30.7 PTPRC MYC CD38
22 leprosy 3 30.6 IL6 CXCL8 CD40LG
23 erythema elevatum diutinum 30.6 CXCL8 CD40LG
24 interstitial nephritis 30.6 ICOSLG CD40LG B2M
25 anemia, autoimmune hemolytic 30.6 IGHV4-38-2 ICOSLG CD40LG CD19
26 essential thrombocythemia 30.6 MYC IL6 CXCL8 CD40LG
27 gamma heavy chain disease 30.6 SDC1 IGHV4-38-2 CD40LG
28 cytomegalovirus infection 30.5 IL6 CXCL8 B2M
29 leptospirosis 30.5 IL6 CXCL8 CD40LG
30 sclerosing cholangitis 30.5 IL6 CXCL8 CD40LG
31 retinal vein occlusion 30.5 IL6 CXCL8 CD40LG
32 heavy chain disease 30.5 MYOM2 CD79A CD40LG
33 leukemia, chronic myeloid 30.5 PTPRC MYC MIR125A CD38 CD19
34 immune deficiency disease 30.5 PTPRC IL6 ICOSLG CD79A CD40LG CD38
35 skin disease 30.5 MIR125A IL6 ICOSLG CXCL8 CD79A CD40LG
36 agammaglobulinemia 30.5 IL6 ICOSLG CD79A CD40LG CD19
37 multicentric castleman disease 30.5 SDC1 IL6 CD79A CD38
38 syphilis 30.4 IL6 CD79A CD40LG B2M
39 lymphoma 30.4 PVT1 PTPRC MYC IL6 CD40LG CD38
40 pancytopenia 30.4 PTPRC NCAM1 IL6 CD40LG CD19
41 burkitt lymphoma 30.4 PVT1 MYC IL6 CD40LG CD19
42 toxoplasmosis 30.4 IL6 CD79A CD40LG
43 acquired immunodeficiency syndrome 30.4 MYC IL6 CD79A CD40LG CD38 B2M
44 optic nerve disease 30.4 IL6 ICOSLG CD40LG CD19
45 arteries, anomalies of 30.3 MIR455 MIR125A IL6 ICOSLG
46 autoimmune disease 30.3 IL6 ICOSLG CXCL8 CD79A CD40LG
47 marginal zone b-cell lymphoma 30.3 SDC1 IGHV4-38-2 CD79A CD40LG CD38 CD19
48 alpha chain disease 30.3 MYOM2 CD79A CD40LG CD19
49 bone disease 30.3 SDC1 IL6 ICOSLG CXCL8 B2M
50 respiratory failure 30.2 SDC1 IL6 CXCL8 CD40LG

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Deficiency Anemia Heart Disease
Monoclonal Paraproteinemia Neutropenia
Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 B2M CD19 CD79A IL6 MYC PTPRC

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 641)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phentolamine Approved Phase 4 50-60-2 5775
2
Apixaban Approved Phase 4 503612-47-3 10182969
3
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
5
Epirubicin Approved Phase 4 56420-45-2 41867
6
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
7
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
8
Ofloxacin Approved Phase 4 82419-36-1 4583
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Liraglutide Approved Phase 4 204656-20-2 44147092
11
Glucagon Approved Phase 4 16941-32-5
12
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
15
Pirarubicin Investigational Phase 4 72496-41-4
16 Anti-Retroviral Agents Phase 4
17 Anti-HIV Agents Phase 4
18 Plerixafor octahydrochloride Phase 4
19 Antithrombins Phase 4
20 Antithrombin III Phase 4
21 Serine Proteinase Inhibitors Phase 4
22 Factor Xa Inhibitors Phase 4
23 Penicillin G Benzathine Phase 4
24 Penicillin G Procaine Phase 4
25 penicillins Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Platelet Aggregation Inhibitors Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Antipyretics Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Hypoglycemic Agents Phase 4
32 Glucagon-Like Peptide 1 Phase 4
33 Incretins Phase 4
34 Adjuvants, Immunologic Phase 4
35 Mitogens Phase 4
36 Hematinics Phase 4
37 Epoetin alfa Phase 4 113427-24-0
38
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
39
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
40
Pamidronate Approved Phase 3 40391-99-9 4674
41
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
42
deoxycholic acid Approved Phase 3 83-44-3 222528
43
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
44
Sulfamethoxazole Approved Phase 3 723-46-6 5329
45
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
47
Ethanol Approved Phase 3 64-17-5 702
48
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
49
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
50
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449

Interventional clinical trials:

(show top 50) (show all 2942)
# Name Status NCT ID Phase Drugs
1 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
2 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
3 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
5 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
6 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
7 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
8 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
9 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
10 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
11 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
12 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
13 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
14 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
15 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
16 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
17 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
18 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
19 REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
20 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
21 Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects Completed NCT02056210 Phase 4 Mozobil
22 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
23 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Recruiting NCT04348006 Phase 4 Bortezomib 3.5 MG
24 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
25 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
26 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
27 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
28 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
29 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
30 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
31 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
32 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
33 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Active, not recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
34 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
35 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Not yet recruiting NCT04352439 Phase 4 Aspirin
36 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Not yet recruiting NCT02920190 Phase 4 Liraglutide
37 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
38 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
39 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
40 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
41 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
42 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
43 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
44 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
45 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
46 Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
47 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
48 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
49 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
50 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

40
T Cells, Bone, Bone Marrow, B Cells, Myeloid, Testes, Breast

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 1302)
# Title Authors PMID Year
1
Untreated plasmacytoma of bone containing macroscopic intralesional fat and mimicking intraosseous lipoma: A case report and review of the literature. 61
32208179 2020
2
Extramedullary multiple myeloma involving the liver and periportal lymph node, diagnosed by EUS-FNA in a patient with cirrhosis. 61
32191820 2020
3
Crystalglobulinemia manifested as acute renal failure and thrombotic vasculopathy. 61
32533290 2020
4
Analysis of neutrophil gelatinase-associated lipocalin, vascular endothelial growth factor, and soluble receptor for advanced glycation end-products in bone marrow supernatant in hematologic malignancies. 61
32304694 2020
5
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. 61
32533060 2020
6
High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification. 61
32447782 2020
7
Skin and Nerve Neovascularization in POEMS Syndrome: Insights From a Small Cohort. 61
32296845 2020
8
Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. 61
32243509 2020
9
Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma? 61
32576503 2020
10
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. 61
31780812 2020
11
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. 61
32107537 2020
12
Trabeculectomy in an unsuspected extramedullary iris-ciliary body plasmacytoma. 61
32314602 2020
13
Approach to the Diagnosis of Amyloidosis. 61
32425373 2020
14
Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report. 61
32299429 2020
15
C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. 61
32103167 2020
16
Thrombosis revealing POEMS syndrome. About a case. 61
32162605 2020
17
High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. 61
32248194 2020
18
Amyloidosis as a Systemic Disease in Context. 61
32145867 2020
19
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. 61
31815313 2020
20
Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. 61
32295695 2020
21
Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. 61
32145862 2020
22
A Case of Dual Positive Glomerulonephritis With Plasma Cell Dyscrasia. 61
32081655 2020
23
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. 61
32079692 2020
24
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. 61
31734019 2020
25
Dissecting racial disparities in multiple myeloma. 61
32066732 2020
26
[Transthyretin amyloid cardiomyopathy]. 61
32089152 2020
27
An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium. 61
32052135 2020
28
Paraprotein implicated in hardware failures in nucleic acid testing of blood donors. 61
31777099 2020
29
Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. 61
31736101 2020
30
PIWI-Interacting RNA-004800 Is Regulated by S1P Receptor Signaling Pathway to Keep Myeloma Cell Survival. 61
32351883 2020
31
A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. 61
31940000 2020
32
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. 61
31918690 2020
33
Essential Thrombocythaemia with Concomitant Waldenström Macroglobulinaemia: Case Report and Literature Review. 61
32425546 2020
34
An autopsy case of amyloid tubulopathy exhibiting characteristic spheroid-type deposition. 61
31932919 2020
35
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. 61
31844041 2019
36
Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α. 61
31650289 2019
37
Differential diagnosis between bone relapse of breast cancer and lambda light chain multiple myeloma: role of the clinical biochemist. 61
30799772 2019
38
Cutaneous Nodular Amyloidosis: A Disfiguring Aspect of the Face. 61
31268923 2019
39
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. 61
31748515 2019
40
Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. 61
31403474 2019
41
The spectrum of malignancies presenting with neurological manifestations: A prospective observational study. 61
31803680 2019
42
Amyloid-Associated Alopecia: A Reappraisal Including Its Pathophysiology. 61
30839340 2019
43
Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study. 61
31702615 2019
44
Cardiac amyloidosis: the need for early diagnosis. 61
31359320 2019
45
Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. 61
31767606 2019
46
Plasma cell leukemia with plasmablastic morphology in a dog. 61
31609183 2019
47
Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. 61
31587789 2019
48
Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. 61
31207062 2019
49
Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding. 61
31379060 2019
50
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1. 61
31452083 2019

Variations for Plasma Cell Neoplasm

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

Pathways related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 IL6 ICOSLG CXCL8 CD40LG B2M
2
Show member pathways
12.61 MYC IL6 CXCL8 CD19 B2M
3 12.32 PTPRC NCAM1 CD79A CD40LG CD38 CD19
4
Show member pathways
12.22 PTPRC MYC CD79A CD19
5 12.11 PTPRC MYC IL6 CXCL8
6 11.97 SDC1 PTPRC NCAM1 ICOSLG CD40LG
7
Show member pathways
11.45 IL6 CXCL8 CD40LG
8 11.42 PTPRC NCAM1 IL6 CD38 CD19
9 11.41 SDC1 PTPRC NCAM1 IL6 CD79A CD19
10 11.37 SDC1 IL6 CXCL8 CD40LG
11 11.34 MYC IL6 CXCL8
12 11.28 MYC IL6 CXCL8
13 11.23 SDC1 PTPRC NCAM1 IL6 CD79A CD38
14 11.2 PTPRC CD79A CD40LG CD19

GO Terms for Plasma Cell Neoplasm

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 SDC1 PTPRC NCAM1 CD40LG CD38 B2M
2 external side of plasma membrane GO:0009897 9.28 SDC1 PTPRC NCAM1 IGHV4-38-2 ICOSLG CD79A

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 MYC MAEA IL6 CD40LG CD38
2 regulation of immune response GO:0050776 9.62 ICOSLG CD40LG CD19 B2M
3 B cell differentiation GO:0030183 9.54 PTPRC CD79A CD40LG
4 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.43 PTPRC MIR125A
5 positive regulation of T cell proliferation GO:0042102 9.43 PTPRC IL6 CD40LG
6 response to molecule of bacterial origin GO:0002237 9.4 CXCL8 B2M
7 B cell proliferation GO:0042100 9.33 PTPRC CD79A CD40LG
8 negative regulation of vascular endothelial growth factor production GO:1904046 9.13 MIR361 MIR20B MIR125A
9 B cell receptor signaling pathway GO:0050853 9.02 PTPRC IGHV4-38-2 CD79A CD38 CD19

Sources for Plasma Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....